Leerink Partnrs Has Positive Estimate for HIMS Q4 Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Leerink Partnrs upped their Q4 2024 earnings estimates for Hims & Hers Health in a report released on Tuesday, October 29th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $0.07 for the quarter, up from their prior estimate of $0.06. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q1 2025 earnings at $0.07 EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.39 EPS.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm’s quarterly revenue was up 51.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.03) earnings per share.

HIMS has been the topic of several other reports. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Bank of America increased their price target on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Piper Sandler restated a “neutral” rating and issued a $18.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Needham & Company LLC started coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Finally, Truist Financial lifted their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.21.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $19.06 on Wednesday. The company has a 50 day moving average price of $17.89 and a 200-day moving average price of $18.00. Hims & Hers Health has a 1-year low of $5.76 and a 1-year high of $25.74. The firm has a market cap of $4.09 billion, a price-to-earnings ratio of 238.25 and a beta of 1.06.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,334 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total value of $40,378.20. Following the completion of the sale, the insider now owns 164,475 shares of the company’s stock, valued at approximately $2,845,417.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 2,334 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total transaction of $40,378.20. Following the transaction, the insider now directly owns 164,475 shares of the company’s stock, valued at $2,845,417.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at $551,777.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 858,665 shares of company stock valued at $15,148,890. Corporate insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its position in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after acquiring an additional 1,603 shares during the last quarter. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC increased its holdings in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Van ECK Associates Corp purchased a new stake in Hims & Hers Health in the second quarter valued at approximately $111,000. Finally, Amalgamated Bank lifted its stake in Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.